ENG and neoplasm: Indeed, Lm vaccines targeting tumor-associated angiogenic proteins, including CD105 and VEGFR2, have demonstrated inhibited tumor growth [97,98,99,100] as well as the ability to induce secondary antitumor immune responses via epitope spreading [98,99].